Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 175

1.
2.

Healthcare related transmission of Pneumocystis pneumonia: From key insights toward comprehensive prevention.

de Boer MGJ, Walzer PD, Mori S.

Transpl Infect Dis. 2018 Oct;20(5):e12942. doi: 10.1111/tid.12942. Epub 2018 Jun 28. Review.

PMID:
29873156
3.

Effects of clinical and environmental factors on bronchoalveolar antibody responses to Pneumocystis jirovecii: A prospective cohort study of HIV+ patients.

Blount RJ, Daly KR, Fong S, Chang E, Grieco K, Greene M, Stone S, Balmes J, Miller RF, Walzer PD, Huang L.

PLoS One. 2017 Jul 10;12(7):e0180212. doi: 10.1371/journal.pone.0180212. eCollection 2017.

4.

Humoral immune responses to Pneumocystis jirovecii antigens in HIV-infected and uninfected young children with pneumocystis pneumonia.

Djawe K, Daly KR, Levin L, Zar HJ, Walzer PD.

PLoS One. 2013 Dec 26;8(12):e82783. doi: 10.1371/journal.pone.0082783. eCollection 2013.

5.

Ambient air pollution associated with suppressed serologic responses to Pneumocystis jirovecii in a prospective cohort of HIV-infected patients with Pneumocystis pneumonia.

Blount RJ, Djawe K, Daly KR, Jarlsberg LG, Fong S, Balmes J, Miller RF, Walzer PD, Huang L; International HIV-associated Opportunistic Pneumonias Study.

PLoS One. 2013 Nov 13;8(11):e80795. doi: 10.1371/journal.pone.0080795. eCollection 2013.

6.

Antibody responses against Pneumocystis jirovecii in health care workers over time.

Fong S, Daly KR, Tipirneni R, Jarlsberg LG, Djawe K, Koch JV, Swartzman A, Roth B, Walzer PD, Huang L.

Emerg Infect Dis. 2013 Oct;19(10):1612-9. doi: 10.3201/eid1910.121836.

7.

The ecology of pneumocystis: perspectives, personal recollections, and future research opportunities.

Walzer PD.

J Eukaryot Microbiol. 2013 Nov-Dec;60(6):634-45. doi: 10.1111/jeu.12072. Epub 2013 Sep 3. Review.

8.

Pneumocystis pneumonia associated with human immunodeficiency virus.

Miller RF, Huang L, Walzer PD.

Clin Chest Med. 2013 Jun;34(2):229-41. doi: 10.1016/j.ccm.2013.02.001. Epub 2013 Apr 8. Review.

PMID:
23702173
9.

Serologic responses to recombinant Pneumocystis jirovecii major surface glycoprotein among Ugandan patients with respiratory symptoms.

Blount RJ, Jarlsberg LG, Daly KR, Worodria W, Davis JL, Cattamanchi A, Djawe K, Andama A, Koch J, Walzer PD, Huang L; International HIV-Associated Opportunistic Pneumonias (IHOP) Study.

PLoS One. 2012;7(12):e51545. doi: 10.1371/journal.pone.0051545. Epub 2012 Dec 21.

10.

Environmental risk factors for Pneumocystis pneumonia hospitalizations in HIV patients.

Djawe K, Levin L, Swartzman A, Fong S, Roth B, Subramanian A, Grieco K, Jarlsberg L, Miller RF, Huang L, Walzer PD.

Clin Infect Dis. 2013 Jan;56(1):74-81. doi: 10.1093/cid/cis841. Epub 2012 Oct 5.

11.

A prognostic scoring tool for identification of patients at high and low risk of death from HIV-associated Pneumocystis jirovecii pneumonia.

Armstrong-James D, Copas AJ, Walzer PD, Edwards SG, Miller RF.

Int J STD AIDS. 2011 Nov;22(11):628-34. doi: 10.1258/ijsa.2011.011040.

PMID:
22096046
12.

HIV-associated Pneumocystis pneumonia.

Huang L, Cattamanchi A, Davis JL, den Boon S, Kovacs J, Meshnick S, Miller RF, Walzer PD, Worodria W, Masur H; International HIV-associated Opportunistic Pneumonias (IHOP) Study; Lung HIV Study.

Proc Am Thorac Soc. 2011 Jun;8(3):294-300. doi: 10.1513/pats.201009-062WR. Review.

13.

Serologic responses to pneumocystis proteins in HIV patients with and without Pneumocystis jirovecii pneumonia.

Gingo MR, Lucht L, Daly KR, Djawe K, Palella FJ, Abraham AG, Bream JH, Witt MD, Kingsley LA, Norris KA, Walzer PD, Morris A.

J Acquir Immune Defic Syndr. 2011 Jul 1;57(3):190-6. doi: 10.1097/QAI.0b013e3182167516.

14.

Decreased serum antibody responses to recombinant pneumocystis antigens in HIV-infected and uninfected current smokers.

Crothers K, Daly KR, Rimland D, Goetz MB, Gibert CL, Butt AA, Justice AC, Djawe K, Levin L, Walzer PD.

Clin Vaccine Immunol. 2011 Mar;18(3):380-6. doi: 10.1128/CVI.00421-10. Epub 2010 Dec 29.

15.

Serum antibody levels to the Pneumocystis jirovecii major surface glycoprotein in the diagnosis of P. jirovecii pneumonia in HIV+ patients.

Djawe K, Huang L, Daly KR, Levin L, Koch J, Schwartzman A, Fong S, Roth B, Subramanian A, Grieco K, Jarlsberg L, Walzer PD.

PLoS One. 2010 Dec 9;5(12):e14259. doi: 10.1371/journal.pone.0014259.

16.

Seroepidemiological study of Pneumocystis jirovecii infection in healthy infants in Chile using recombinant fragments of the P. jirovecii major surface glycoprotein.

Djawe K, Daly KR, Vargas SL, Santolaya ME, Ponce CA, Bustamante R, Koch J, Levin L, Walzer PD.

Int J Infect Dis. 2010 Dec;14(12):e1060-6. doi: 10.1016/j.ijid.2010.07.003.

17.

Seasonal variation in mortality of Pneumocystis jirovecii pneumonia in HIV-infected patients.

Miller RF, Evans HE, Copas AJ, Huggett JF, Edwards SG, Walzer PD.

Int J STD AIDS. 2010 Jul;21(7):497-503. doi: 10.1258/ijsa.2010.010148.

PMID:
20852200
18.

Echinocandin treatment of pneumocystis pneumonia in rodent models depletes cysts leaving trophic burdens that cannot transmit the infection.

Cushion MT, Linke MJ, Ashbaugh A, Sesterhenn T, Collins MS, Lynch K, Brubaker R, Walzer PD.

PLoS One. 2010 Jan 29;5(1):e8524. doi: 10.1371/journal.pone.0008524.

19.

Healthcare worker occupation and immune response to Pneumocystis jirovecii.

Tipirneni R, Daly KR, Jarlsberg LG, Koch JV, Swartzman A, Roth BM, Walzer PD, Huang L.

Emerg Infect Dis. 2009 Oct;15(10):1590-7. doi: 10.3201/eid1510.090207.

20.

Evidence for high prevalence of Pneumocystis jirovecii exposure among Cameroonians.

Nkinin SW, Daly KR, Walzer PD, Ndzi ES, Asonganyi T, Respaldiza N, Medrano FJ, Kaneshiro ES.

Acta Trop. 2009 Nov;112(2):219-24. doi: 10.1016/j.actatropica.2009.07.030. Epub 2009 Aug 7.

21.

Preclinical drug discovery for new anti-pneumocystis compounds.

Cushion MT, Walzer PD.

Curr Med Chem. 2009;16(20):2514-30. Review.

PMID:
19601796
22.

Geographical variation in serological responses to recombinant Pneumocystis jirovecii major surface glycoprotein antigens.

Daly K, Koch J, Respaldiza N, de la Horra C, Montes-Cano MA, Medrano FJ, Varela JM, Calderon EJ, Walzer PD.

Clin Microbiol Infect. 2009 Oct;15(10):937-42. doi: 10.1111/j.1469-0691.2009.02716.x. Epub 2009 Mar 21.

23.

Effects of surfactant protein-A on the interaction of Pneumocystis murina with its host at different stages of the infection in mice.

Linke MJ, Ashbaugh AA, Koch JV, Levin L, Tanaka R, Walzer PD.

J Eukaryot Microbiol. 2009 Jan-Feb;56(1):58-65. doi: 10.1111/j.1550-7408.2008.00363.x.

24.

Long-term serologic responses to the Pneumocystis jirovecii major surface glycoprotein in HIV-positive individuals with and without P. jirovecii infection.

Walzer PD, Djawe K, Levin L, Daly KR, Koch J, Kingsley L, Witt M, Golub ET, Bream JH, Taiwo B, Morris A.

J Infect Dis. 2009 May 1;199(9):1335-44. doi: 10.1086/597803.

25.

Pneumocystis murina colonization in immunocompetent surfactant protein A deficient mice following environmental exposure.

Linke MJ, Ashbaugh AD, Demland JA, Walzer PD.

Respir Res. 2009 Feb 19;10:10. doi: 10.1186/1465-9921-10-10.

26.

Early predictors of mortality from Pneumocystis jirovecii pneumonia in HIV-infected patients: 1985-2006.

Walzer PD, Evans HE, Copas AJ, Edwards SG, Grant AD, Miller RF.

Clin Infect Dis. 2008 Feb 15;46(4):625-33. doi: 10.1086/526778.

28.

Antibody response to Pneumocystis jirovecii major surface glycoprotein.

Daly KR, Huang L, Morris A, Koch J, Crothers K, Levin L, Eiser S, Satwah S, Zucchi P, Walzer PD.

Emerg Infect Dis. 2006 Aug;12(8):1231-7.

29.

In vitro selection and in vivo efficacy of piperazine- and alkanediamide-linked bisbenzamidines against Pneumocystis pneumonia in mice.

Cushion MT, Walzer PD, Ashbaugh A, Rebholz S, Brubaker R, Vanden Eynde JJ, Mayence A, Huang TL.

Antimicrob Agents Chemother. 2006 Jul;50(7):2337-43.

30.

Highly active anti-Pneumocystis carinii compounds in a library of novel piperazine-linked bisbenzamidines and related compounds.

Cushion MT, Walzer PD, Collins MS, Rebholz S, Vanden Eynde JJ, Mayence A, Huang TL.

Antimicrob Agents Chemother. 2004 Nov;48(11):4209-16.

31.

Current epidemiology of Pneumocystis pneumonia.

Morris A, Lundgren JD, Masur H, Walzer PD, Hanson DL, Frederick T, Huang L, Beard CB, Kaplan JE.

Emerg Infect Dis. 2004 Oct;10(10):1713-20. Review.

32.

Novel bisbenzamidines as potential drug candidates for the treatment of Pneumocystis carinii pneumonia.

Vanden Eynde JJ, Mayence A, Huang TL, Collins MS, Rebholz S, Walzer PD, Cushion MT.

Bioorg Med Chem Lett. 2004 Sep 6;14(17):4545-8.

PMID:
15357989
33.

Enzyme-linked immunosorbent assay and serologic responses to Pneumocystis jiroveci.

Daly KR, Koch J, Levin L, Walzer PD.

Emerg Infect Dis. 2004 May;10(5):848-54.

34.
36.

New rat model of Pneumocystis pneumonia induced by anti-CD4(+) T-lymphocyte antibodies.

Thullen TD, Ashbaugh AD, Daly KR, Linke MJ, Steele PE, Walzer PD.

Infect Immun. 2003 Nov;71(11):6292-7.

37.

Serologic responses to epitopes of the major surface glycoprotein of Pneumocystis jiroveci differ in human immunodeficiency virus-infected and uninfected persons.

Daly KR, Fichtenbaum CJ, Tanaka R, Linke MJ, O'Bert R, Thullen TD, Hui MS, Smulian AG, Walzer PD.

J Infect Dis. 2002 Sep 1;186(5):644-51. Epub 2002 Aug 9.

PMID:
12195351
38.

Use of terbinafine in mouse and rat models of Pneumocystis carinii pneumonia.

Walzer PD, Ashbaugh A.

Antimicrob Agents Chemother. 2002 Feb;46(2):514-6.

39.

Anti-human immunodeficiency virus drugs are ineffective against Pneumocystis carinii in vitro and in vivo.

Walzer PD, Ashbaugh A, Collins M, Cushion MT.

J Infect Dis. 2001 Nov 15;184(10):1355-7. Epub 2001 Sep 28. Erratum in: J Infect Dis 2002 Jun 1;185(11):1696.

PMID:
11679930
40.

In vitro and in vivo effects of quinupristin-dalfopristin against Pneumocystis carinii.

Walzer PD, Ashbaugh A, Collins M, Cushion MT.

Antimicrob Agents Chemother. 2001 Nov;45(11):3234-7.

41.

Immunosuppressed surfactant protein A-deficient mice have increased susceptibility to Pneumocystis carinii infection.

Linke MJ, Harris CE, Korfhagen TR, McCormack FX, Ashbaugh AD, Steele P, Whitsett JA, Walzer PD.

J Infect Dis. 2001 Mar 15;183(6):943-52. Epub 2001 Feb 15.

PMID:
11237812
42.

Geographic clustering of Pneumocystis carinii pneumonia in patients with HIV infection.

Dohn MN, White ML, Vigdorth EM, Ralph Buncher C, Hertzberg VS, Baughman RP, George Smulian A, Walzer PD.

Am J Respir Crit Care Med. 2000 Nov;162(5):1617-21.

PMID:
11069785
43.

Immunological features of Pneumocystis carinii infection in humans.

Walzer PD.

Clin Diagn Lab Immunol. 1999 Mar;6(2):149-55. Review. No abstract available.

44.

Pneumocystis carinii: a historical perspective.

Walzer PD.

Semin Respir Infect. 1998 Dec;13(4):279-82.

PMID:
9872623
45.

Immunization with the major surface glycoprotein of Pneumocystis carinii elicits a protective response.

Theus SA, Smulian AG, Steele P, Linke MJ, Walzer PD.

Vaccine. 1998 Jul;16(11-12):1149-57.

PMID:
9682373
46.

Cell wall antigens of Pneumocystis carinii trophozoites and cysts: purification and carbohydrate analysis of these glycoproteins.

De Stefano JA, Myers JD, Du Pont D, Foy JM, Theus SA, Walzer PD.

J Eukaryot Microbiol. 1998 May-Jun;45(3):334-43.

PMID:
9627993
47.

Zymolyase treatment exposes p55 antigen of Pneumocystis carinii.

Broomall KR, Morris RE, Walzer PD, Smulian AG.

J Eukaryot Microbiol. 1998 May-Jun;45(3):284-9.

PMID:
9627988
49.

In vitro cytolytic activity of lymphocytes against Pneumocystis carinii.

Theus SA, Walzer PD.

J Eukaryot Microbiol. 1997 Nov-Dec;44(6):25S-27S. No abstract available.

PMID:
9508415

Supplemental Content

Loading ...
Support Center